Drug development takes a great deal of time, money and effort. While future profits play a big factor in which diseases gets prioritized, advocacy and research incentives can also tilt the scale.
Rigor académico, oficio periodístico
Artículos sobre Rare diseases
Mostrando 1 - 20 de 27 artículos
Warmer ocean waters are fueling the spread of the bacteria Vibrio vulnificus. Infections can lead to a rare but fatal condition called necrotizing fasciitis.
Animals, including the ones that live in our homes, can carry all kinds of illnesses. Most of the time it’s not a problem, but here’s what you should do to avoid getting sick.
Spinal muscular atrophy, a disease the author of the article suffers, is one of the genetic diseases with the highest associated mortality. It is also the most expensive to cure.
Although there is no cure for this disorder, there are treatments that can help alleviate symptoms.
Sildenafil — better known as Viagra — may be helpful in treating lung diseases like pulmonary arterial hypertension and idiopathic pulmonary fibrosis, for which there are few effective treatments.
Deciphering the biological pathways behind rare genetic diseases often involves assembling a team of specialists to work closely with the family members of those affected.
Tay-Sachs is a rare and fatal neurodegerative disorder that most commonly affects children. Researchers have developed the first Tay-Sachs treatment to reach clinical trials.
Record-breaking technology can sequence an entire human genome in a matter of hours. The work could be a lifeline for people suffering from the more than 5,000 known rare genetic diseases.
Spinal muscular dystrophy affects at least 1 in 10,000 people, but new drugs have given hope to those suffering from this rare disease.
‘Orphan drugs’ with high price points are being tested as treatments for COVID-19. There’s a better way to spur low-cost innovation for new drugs.
A rare disease is one that affects less that five in 10,000 people. There are about 7,000 known rare diseases.
A new agency and money for drugs for rare diseases are only very partial steps on the road towards what Canada really needs: a national pharmacare plan.
Despite the fact that rare diseases aren’t actually so rare, it appears they suffer from a branding problem in Canada.
In 2030, there is a boom in precision medicine, where diseases – from cancer to dementia – are defined and targeted more specifically with a focus on their molecular makeup.
Specialty prescription drugs are responsible for countless medical miracles, but their high price tag is the main reason health care costs are out of control.
Rare diseases may only affect a handful of people but their treatment benefits everyone.
Children’s cancer is a rare disease, which means the market is small and pharmaceutical companies have few incentives to develop drugs for these cancers.
Policy moves to benefit patients are now benefiting business.
Gigantism and acromegaly are rare conditions where a benign tumour causes excessive production of growth hormone (GH), which stimulates the growth of the skeleton and all tissues in the body.
Principales colaboradores
-
Distinguished Professor of Pharmacy Practice, University of Connecticut
-
Curtin Research Fellow, Curtin University
-
Research Fellow, Cardiff University
-
International adviser and Fellow, Royal College of Pathologists
-
Researcher and Head of Division in Earth Sciences, Natural History Museum
-
Professor and Director of the Clinical Anatomy Learning Centre, Lancaster University
-
Professor of Veterinary Infectious Diseases, University of Liverpool and International Livestock Research Institute, Kenya, University of Liverpool
-
Professor, The University of Queensland
-
Professor of Pharmacoeconomics, Co-director of the Centre for Health Economics & Medicines Evaluation, Bangor University
-
Senior Lecturer in Accounting and Finance, University of Liverpool
-
Professor, Children's Cancer Institute
-
Associate Professor (conjoint), Children's Cancer Institute
-
Joel Lexchin es Amigo de The Conversation.
Professor Emeritus of Health Policy and Management, York University, Canada
-
Professor, Central Clinical School, Monash University
-
John Curtin Distinguished Professor, Molecular and Life Sciences, Curtin University
